Seeking Alpha复盘雅培二季度业绩后观点分歧，未披露新的公司催化

Abbott Laboratories (ABT) delivered a strong Q2 2026 performance that surprised Wall Street, with the healthcare giant posting a double beat on both top and bottom lines on July 16, 2026. The earnings announcement sparked a 14% stock surge, with shares now trading around $104-$105. The company returned $2.1 billion to shareholders during the quarter, underscoring its commitment to capital returns.
Despite the sharp rally, analyst sentiment remains divided, with some experts maintaining bullish ratings while others have adopted a more neutral stance following the post-earnings price appreciation.
What Do Seeking Alpha Analysts Say About Abbott's Future?
Supporters pointed to Abbott's diversified business model spanning diagnostics, nutrition, and medical devices, with management targeting more than 7% organic growth. The company's elite "Dividend King" status, A+ S&P credit rating with a stable outlook, and the recently acquired Exact Sciences business delivering double-digit growth in the new Cancer Diagnostic segment further bolster the positive case. Some analysts see the shares trading at a significant discount to fair value with substantial upside potential.
Critics, however, highlighted integration risks associated with the Exact Sciences acquisition, which introduces balance sheet and bottom-line concerns. They also cautioned that the seasonally softer third-quarter trading months could present near-term underperformance risks.
Here's a breakdown of what some analysts had to say:
What Do the Quant Ratings Say?
Abbott Laboratories currently carries a Hold rating from Seeking Alpha's quant system that reflects the company's mixed technical and fundamental picture following the post-earnings surge.
Profitability (A+): Abbott earns an A+ profitability grade, supported by strong cash flow generation and $2.1 billion returned to shareholders in the second quarter through dividends and share repurchases.
Valuation (D): While some analysts estimate Abbott shares trade about 26% below intrinsic value based on normalized earnings projections of $5.80 per share at an 18x multiple, the stock receives a D valuation grade from Seeking Alpha's Quant system, reflecting relatively expensive valuation metrics compared with peers.
Growth (D-): Abbott continues to benefit from strength in its Medical Devices business and contributions from the recently acquired Exact Sciences business. However, the stock carries a D- growth grade, indicating relatively modest growth metrics relative to peers.
Momentum (C+): Abbott's C+ momentum grade reflects improved sentiment following its 14% post-earnings rally, although the stock's overall technical picture remains mixed.
Earnings Revisions (A-): Abbott earns an A- earnings revisions grade, reflecting positive analyst estimate revisions following its recent earnings report and updated guidance, signaling improving earnings expectations.
What's the latest news on Abbott?
Abbott's second-quarter performance was driven by broad-based strength across its businesses, with revenue rising about 13% year over year to $12.6 billion, led by Diagnostics and Medical Devices. Diagnostics revenue climbed about 42% to $3.1 billion, supported by approximately $919 million in Cancer Diagnostics revenue following the Exact Sciences acquisition. Medical Devices revenue increased about 9% to $5.9 billion, while Established Pharmaceuticals grew about 8%, helping offset a decline in Nutrition sales.
Abbott also maintained its A+ S&P credit rating with a stable outlook, providing financial flexibility to support strategic investments, acquisitions, and shareholder returns.